Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CHMAOTCMKTS:ENDVNASDAQ:MRNSNASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHMAChiasma$3.76$4.01$2.77▼$5.74$217.68M1.282.12 million shs147 shsENDVEndonovo Therapeutics$0.00$0.00$0.00▼$0.00$240K-1.377.34 million shs10,000 shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.81 million shs260 shsSPROSpero Therapeutics$2.90$1.72$0.51▼$3.09$162.14M1.331.20 million shs639,760 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHMAChiasma0.00%0.00%0.00%0.00%0.00%ENDVEndonovo Therapeutics0.00%0.00%+100.00%0.00%-81.82%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-53.07%SPROSpero Therapeutics-1.36%-1.02%+12.40%+317.87%+123.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHMAChiasmaN/AN/AN/AN/AN/AN/AN/AN/AENDVEndonovo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMRNSMarinus Pharmaceuticals2.2652 of 5 stars3.20.00.04.20.61.70.6SPROSpero Therapeutics4.2816 of 5 stars3.35.00.04.72.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHMAChiasma 0.00N/AN/AN/AENDVEndonovo Therapeutics 0.00N/AN/AN/AMRNSMarinus Pharmaceuticals 2.40Hold$3.92613.29% UpsideSPROSpero Therapeutics 2.50Moderate Buy$5.0072.41% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHMAChiasma$1.11M196.11N/AN/A$1.59 per share2.36ENDVEndonovo Therapeutics$10K24.13$0.02 per share0.01($0.08) per share0.00MRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77SPROSpero Therapeutics$47.98M3.38N/AN/A$0.85 per share3.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHMAChiasma-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/AENDVEndonovo Therapeutics-$2.80MN/A0.00∞N/AN/AN/AN/AN/AMRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)SPROSpero Therapeutics-$68.57M-$1.28N/AN/AN/A-156.48%-123.50%-58.96%8/4/2025 (Estimated)Latest MRNS, SPRO, CHMA, and ENDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SPROSpero Therapeutics-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHMAChiasmaN/AN/AN/AN/AN/AENDVEndonovo TherapeuticsN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHMAChiasmaN/A7.917.08ENDVEndonovo TherapeuticsN/AN/AN/AMRNSMarinus PharmaceuticalsN/A1.661.47SPROSpero TherapeuticsN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHMAChiasma61.68%ENDVEndonovo TherapeuticsN/AMRNSMarinus Pharmaceuticals98.80%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipCHMAChiasma8.30%ENDVEndonovo Therapeutics5.61%MRNSMarinus Pharmaceuticals5.46%SPROSpero Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHMAChiasma8557.89 millionN/ANot OptionableENDVEndonovo Therapeutics11.21 billion1.14 billionNot OptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableSPROSpero Therapeutics15055.91 million52.84 millionOptionableMRNS, SPRO, CHMA, and ENDV HeadlinesRecent News About These CompaniesSpero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average - What's Next?July 1 at 3:38 AM | marketbeat.comWhile institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownershipJune 28 at 10:04 AM | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo FinanceJune 26, 2025 | finance.yahoo.comSpero Therapeutics (NASDAQ:SPRO) Upgraded to "Hold" at Wall Street ZenJune 21, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200 Day Moving Average - What's Next?June 19, 2025 | marketbeat.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Up 446.6% in MayJune 11, 2025 | marketbeat.comSpero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsJune 11, 2025 | seekingalpha.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial CorpJune 6, 2025 | marketbeat.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | msn.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | insidermonkey.comGSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMCMay 30, 2025 | pharmabiz.comPSpero Therapeutics rockets on positive Phase III study for tebipenem HBrMay 29, 2025 | thepharmaletter.comTSpero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 MilestoneMay 29, 2025 | msn.comSPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study GoalMay 29, 2025 | zacks.comGSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soarsMay 28, 2025 | endpts.comEGSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 winMay 28, 2025 | fiercebiotech.comFSpero Therapeutics Shares Soar as Trial with GSK Ends Early on EfficacyMay 28, 2025 | marketwatch.comSpero Therapeutics Stock Skyrockets on Strong Phase 3 Trial ResultsMay 28, 2025 | msn.comSpero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring CommitteeMay 28, 2025 | globenewswire.comSpero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2025 | zacks.comSpero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business UpdateMay 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeRussell Rebalance: 3 Stocks Ready to Move HigherBy Chris Markoch | June 20, 2025View Russell Rebalance: 3 Stocks Ready to Move HigherMRNS, SPRO, CHMA, and ENDV Company DescriptionsChiasma NASDAQ:CHMAChiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.Endonovo Therapeutics OTCMKTS:ENDV$0.0002 0.00 (0.00%) As of 09:30 AM EasternEndonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.Marinus Pharmaceuticals NASDAQ:MRNS$0.55 0.00 (-0.16%) As of 02/11/2025Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Spero Therapeutics NASDAQ:SPRO$2.90 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.92 +0.02 (+0.72%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
